SG11201811661TA - Uses of indolinone compounds - Google Patents

Uses of indolinone compounds

Info

Publication number
SG11201811661TA
SG11201811661TA SG11201811661TA SG11201811661TA SG11201811661TA SG 11201811661T A SG11201811661T A SG 11201811661TA SG 11201811661T A SG11201811661T A SG 11201811661TA SG 11201811661T A SG11201811661T A SG 11201811661TA SG 11201811661T A SG11201811661T A SG 11201811661TA
Authority
SG
Singapore
Prior art keywords
international
san diego
del mar
oncternal
therapeutics
Prior art date
Application number
SG11201811661TA
Inventor
Brian Lannutti
Katayoun Jessen
James Breitmeyer
Original Assignee
Oncternal Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncternal Therapeutics Inc filed Critical Oncternal Therapeutics Inc
Publication of SG11201811661TA publication Critical patent/SG11201811661TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111011101 HIM 011010101101111111110111111H1111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/022771 Al 01 February 2018 (01.02.2018) WIP0 I PCT (51) International Patent Classification: CA 92130-2122 (US). JESSEN, Katayoun; C/o Oncter- A61K 31/404 (2006.01) A61K 39/395 (2006.01) nal Therapeutics, Inc., 3525 Del Mar Heights Road, #821, A61K 31/454 (2006.01) A61K 45/06 (2006.01) San Diego, CA 92130-2122 (US). BREITMEYER, James, (21) International Application Number: Bradley; C/o Oncternal Therapeutics, Inc., 3525 Del Mar PCT/US2017/043979 Heights Road, #821, San Diego, CA 92130-2122 (US). (22) International Filing Date: (74) Agent: MALLON, Joseph, J.; Knobbe Martens Olson & 26 July 2017 (26.07.2017) Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA 92614 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/368,707 29 July 2016 (29.07.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/417,572 04 November 2016 (04.11.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/422,504 15 November 2016 (15.11.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/426,107 23 November 2016 (23.11.2016) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/503,238 08 May 2017 (08.05.2017) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/534,067 18 July 2017 (18.07.2017) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: ONCTERNAL THERAPEUTICS, INC. TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. [US/US]; 3525 Del Mar Heights Road, #821, San Diego, (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, — CA 92130-2122 (US). = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: LANNUTTI, Brian; C/o Oncternal Therapeu- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = tics, Inc., 3525 Del Mar Heights Road, #821, San Diego, = (54) Title: USES OF INDOLINONE COMPOUNDS = = = = ....-s. \ = ',. ;:,.; ,••• _ _ , . N N = .. • .‘ = = = ACTIVE INHIBITED K216 • Apoowsis: = • Oneogonosis: - Anchorage - independent growth - Programmed cell death kY - 'rumors in mice - in tumor growth . Altered Gene Expression; — - Altered Gene Expression; Il - I E',232 (ohroman regulator) - 1 E2C2 t VEGF-A (soglogeneMe) -- .1 vEGF - A Il - Alternative Splicing; • Variant ISOlonns: Ir---- - Cyan D1 t$ (activates ce cycle? - Gyart Ma (stows mil cycle) IN - ARID1A-ex18l. (chrome& tegulator) - AR1D1A-ex185 (more-ormogenic) ei ei FIG. 1 0 —..... 00 1-1 N (57) : Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations _ of venetoclax and indolinone derivatives are provided. [Continued on next page] WO 2018/022771 Al IMEDIMOM0101011MERIONIONEEHMHIMEMOIMIE TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with amended claims (Art. 19(1))
SG11201811661TA 2016-07-29 2017-07-26 Uses of indolinone compounds SG11201811661TA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662368707P 2016-07-29 2016-07-29
US201662417572P 2016-11-04 2016-11-04
US201662422504P 2016-11-15 2016-11-15
US201662426107P 2016-11-23 2016-11-23
US201762503238P 2017-05-08 2017-05-08
US201762534067P 2017-07-18 2017-07-18
PCT/US2017/043979 WO2018022771A1 (en) 2016-07-29 2017-07-26 Uses of indolinone compounds

Publications (1)

Publication Number Publication Date
SG11201811661TA true SG11201811661TA (en) 2019-01-30

Family

ID=61011754

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811661TA SG11201811661TA (en) 2016-07-29 2017-07-26 Uses of indolinone compounds

Country Status (11)

Country Link
US (4) US10159660B2 (en)
EP (1) EP3490553A4 (en)
JP (3) JP6885629B2 (en)
KR (2) KR20210095721A (en)
CN (1) CN109789127B (en)
CA (1) CA3029851A1 (en)
MX (1) MX2019000867A (en)
PH (1) PH12019500070A1 (en)
SG (1) SG11201811661TA (en)
TW (2) TWI780061B (en)
WO (1) WO2018022771A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6654197B2 (en) * 2014-10-09 2020-02-26 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Indolinone compounds and uses thereof
EP3436434B1 (en) 2016-03-31 2020-07-08 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
EP3490553A4 (en) * 2016-07-29 2020-03-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds
CN110818611B (en) * 2018-08-13 2023-01-24 中国科学院上海药物研究所 Indolone compounds, preparation method, pharmaceutical composition and application thereof
CA3133376A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
WO2022266491A1 (en) * 2021-06-18 2022-12-22 University Of Maryland, Baltimore Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof
KR20240037280A (en) * 2021-07-16 2024-03-21 셀라토 파마슈티칼즈, 인코포레이티드 Method for preparing liposomal formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (en) 1983-07-22 1991-01-17 Du Pont PHENYLQUINOLINE ACID AND DERIVATIVES AS AN ANTITUARY AGENT.
ATE285769T1 (en) 1998-12-04 2005-01-15 Neurosearch As USE OF ISATINE DERIVATIVES AS ION CHANNEL ACTIVATION AGENTS
UA75054C2 (en) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
ES2243461T3 (en) 2000-02-28 2005-12-01 Sugen, Inc. COMPOUNDS OF 3- (PIROLILLACTONE) -2-INDOLINONE AS QUINASE INHIBITORS.
CN1155572C (en) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 Indole derivatives and its anticancer usage
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
JP4584987B2 (en) 2004-04-30 2010-11-24 アルニラム ファーマスーティカルズ インコーポレイテッド Oligonucleotides containing C5-modified pyrimidines
AR056317A1 (en) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc OXINDOL COMPOUNDS AND PHARMACEUTICAL COMPOSITION
WO2006117414A1 (en) 2005-04-29 2006-11-09 Proyecto De Biomedicina Cima, S.L. Non-human animal sarcoma model
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
CA2953987A1 (en) 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
PT2154966E (en) 2007-04-20 2013-11-13 Univ New York State Res Found Benzimidazoles and pharmaceutical compositions thereof
US8377992B2 (en) 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
US20110218155A1 (en) 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
EA024364B1 (en) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Method for treating multiple myeloma
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
AR078161A1 (en) * 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
CN102516152B (en) 2011-12-12 2014-12-10 华东师范大学 Alpha-difluoro carbonyl substituted chiral tert-alcohol compound, its synthetic method and application thereof
TW201346030A (en) 2012-04-02 2013-11-16 Gradalis Inc Ewing's sarcoma bifunctional shRNA design
CN104395288B (en) * 2012-04-12 2016-12-14 乔治城大学 For treating the method and composition of Ewing sarcoma family tumor
WO2014015153A2 (en) * 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2983670A4 (en) * 2013-04-08 2017-03-08 Pharmacyclics LLC Ibrutinib combination therapy
MX366623B (en) * 2013-04-26 2019-07-16 Beigene Ltd Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones.
KR101500363B1 (en) * 2013-07-01 2015-03-16 현대자동차 주식회사 Power transmission system of hybrid electric vehicle
US20160158246A1 (en) * 2013-08-06 2016-06-09 Oncoethix Gmbh Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
CN103435606A (en) 2013-08-22 2013-12-11 中国药科大学 CDK2 and CSK3beta dual inhibitor and application thereof
WO2015061229A1 (en) 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer
KR20160066554A (en) * 2013-10-25 2016-06-10 파마싸이클릭스 엘엘씨 Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
KR20160079823A (en) * 2013-11-27 2016-07-06 온코에틱스 게엠베하 Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
JP6275846B2 (en) * 2013-12-05 2018-02-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Heteroarylpyridone and aza-pyridone compounds having electrophilic functional groups
JP2017514806A (en) * 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Methods of treating cancer using TOR kinase inhibitor combination therapy
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
WO2016014859A1 (en) * 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
JP2017529332A (en) * 2014-08-28 2017-10-05 オンコエシックス ゲーエムベーハー Method for treating acute myeloid leukemia or acute lymphoblastic leukemia using a pharmaceutical composition comprising a thienotriazolodiazepine compound
JP6654197B2 (en) 2014-10-09 2020-02-26 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Indolinone compounds and uses thereof
EP3436434B1 (en) 2016-03-31 2020-07-08 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
EP3490553A4 (en) * 2016-07-29 2020-03-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds

Also Published As

Publication number Publication date
JP2019522037A (en) 2019-08-08
EP3490553A4 (en) 2020-03-25
KR20190025043A (en) 2019-03-08
TWI780061B (en) 2022-10-11
MX2019000867A (en) 2019-09-16
JP7208659B2 (en) 2023-01-19
KR102282794B1 (en) 2021-07-27
US11285132B2 (en) 2022-03-29
US10159660B2 (en) 2018-12-25
CN109789127B (en) 2022-03-25
JP2021050227A (en) 2021-04-01
EP3490553A1 (en) 2019-06-05
TW201806624A (en) 2018-03-01
CN109789127A (en) 2019-05-21
CA3029851A1 (en) 2018-02-01
US20190022062A1 (en) 2019-01-24
JP6885629B2 (en) 2021-06-16
US20200253927A1 (en) 2020-08-13
CN114569606A (en) 2022-06-03
US20180028495A1 (en) 2018-02-01
JP7182304B2 (en) 2022-12-02
KR20210095721A (en) 2021-08-02
PH12019500070A1 (en) 2019-10-14
US10646470B2 (en) 2020-05-12
JP2021107456A (en) 2021-07-29
WO2018022771A1 (en) 2018-02-01
TW202302089A (en) 2023-01-16
US20220362211A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
SG11201811661TA (en) Uses of indolinone compounds
SG11201808990QA (en) Compositions for topical application of compounds
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201809688RA (en) Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201907023UA (en) Method of reducing neutropenia
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201811559WA (en) Cancer treatment combinations
SG11201809594WA (en) Nicotine particles and compositions
SG11201809751XA (en) Egfr inhibitor compounds
SG11201805001UA (en) Method of treating influenza a
SG11201810940XA (en) Methods of treating pancreatic cancer